This bill modifies Medicare's rules for clinical laboratory testing to reduce administrative burdens. It requires the use of statistically valid sampling (instead of full reporting) for "widely available" tests - defined as tests costing under $1,000 per test with over 100 labs performing them - to determine payment rates starting in 2026. The bill also delays reporting deadlines until 2027, updates how labs are defined for payment purposes, and adds annual payment increase caps (2.5% for common tests in 2024-2025, rising to 5% by 2028). These changes directly affect Medicare-participating labs, particularly independent and hospital-based labs conducting common tests.
This bill expands Medicare Part B coverage to include specific pharmacist services, directly affecting Medicare beneficiaries and pharmacists who provide these services. It adds new coverage for pharmacist evaluations and treatments related to certain illnesses (like COVID-19, flu, or strep throat) and public health emergencies, requiring payment at 80% of the lesser of actual charge or 85% of physician payment rates (100% during emergencies). The bill also prohibits balance billing for these services, ensuring beneficiaries pay only the standard Medicare copayment. These changes aim to improve access to pharmacist care during health crises while aligning payment with existing physician service frameworks.
The HELLPP Act (HR 1634) amends Medicaid to recognize doctors of podiatric medicine (podiatrists) as physicians, enabling them to be reimbursed for services under Medicaid starting January 1, 2024. It also clarifies Medicare’s documentation requirements for therapeutic shoes for people with diabetes, mandating specific written certifications from a managing physician and a podiatrist to confirm medical necessity. These changes directly affect patients with foot conditions, especially those with diabetes, by improving access to podiatrist-provided care and coverage for therapeutic shoes. The bill includes a separate provision strengthening Medicaid program integrity through continuous levies on provider payments, but this does not alter patient coverage. All key provisions take effect on January 1, 2024.
HR 1610 would modernize Medicare coverage for chiropractic care by removing the current restriction that limited beneficiaries to one chiropractic service per visit. It expands coverage to include all services provided by licensed chiropractors within their state-authorized scope, aligning Medicare with VA, military, and private insurance practices. The bill requires chiropractors to complete a Secretary-approved educational webinar to cover non-spinal services, while still allowing payment for spinal manipulation treatments without this requirement. This directly affects Medicare beneficiaries seeking chiropractic care and chiropractors seeking Medicare reimbursement for their services.
This bill expands Medicare coverage for hereditary cancer prevention and management. It requires Medicare to cover genetic testing for individuals with a personal or family history of hereditary cancer mutations, as defined by evidence-based guidelines from organizations like the National Comprehensive Cancer Network. The bill also mandates coverage for risk-reducing surgeries (like mastectomies or oophorectomies) when medically appropriate, and increases the frequency of recommended cancer screenings (such as mammograms, colonoscopies, and breast MRI) to at least annually for those with confirmed hereditary cancer gene mutations. These changes apply to Medicare beneficiaries with specific hereditary cancer risk factors, effective upon the bill's enactment.
This bill makes permanent Medicare coverage for cardiac and pulmonary rehabilitation services delivered via telehealth in patients' homes, which were temporarily allowed during the pandemic. It removes geographic restrictions that previously required in-person visits or limited services to specific locations like clinics. The change directly affects Medicare beneficiaries needing heart or lung rehabilitation and healthcare providers offering these programs. It ensures home-based telehealth visits for cardiac, intensive cardiac, and pulmonary rehabilitation receive the same coverage as in-clinic services under Medicare.
This bill requires the Treasury Secretary to review 10 specific Chinese companies within 60 days to determine if they are responsible for or complicit in serious human rights abuses against Uyghurs and other Muslim groups in Xinjiang, or meet criteria under existing sanctions laws. If determined to meet these criteria, the companies - such as Hikvision, BGI Group, Tiandy Technologies, Alibaba, and ByteDance - would be added to a U.S. sanctions list blocking their assets. The Treasury must then report its findings to Congress, including the reasons for the determination, in an unclassified report with a potential classified annex. The bill directly affects these listed entities by subjecting them to potential U.S. financial sanctions.
HR 1110, the KEEP Telehealth Options Act of 2023, requires the Department of Health and Human Services (HHS) to study pandemic-era telehealth expansions in Medicare, Medicaid, and CHIP programs through December 2024. The bill mandates HHS to report on telehealth service availability, provider reimbursement rules, usage patterns (including by rural, minority, low-income, and elderly populations), and mental health service use. It also directs MedPAC and MACPAC to study access barriers and potential fraud risks in telehealth services during this period. The reports, due within 1-18 months, will inform future policy decisions about telehealth coverage. This legislation focuses on gathering data to evaluate existing telehealth policies, not on changing them.
This bill repeals specific provisions from the Affordable Care Act and its 2010 amendment that restricted certain physician referrals to hospitals under Medicare. It directly affects hospitals and physicians who previously faced limitations on referring Medicare patients to facilities they owned or had financial ties with. The key mechanism restores the original rules that allowed such referrals without the prior restrictions, effectively undoing the 2010 changes. This is a procedural change to existing law, not a new policy.
HR 756, the Foster Care Stabilization Act of 2023, provides $5 million in federal grants to support foster youth under age 26. It awards three demonstration grants (up to $1 million each) to foster care stabilization agencies for emergency relief and improved pre-placement services, directly helping youth waiting for placement or experiencing instability. Key provisions allow funds for hiring staff, providing up to $250 annually in clothing/personal items per youth, food preparation, and preventing abuse/neglect. Agencies must return unused funds after three years and report on outcomes like reduced home transfers and service usage. The bill targets agencies serving foster youth, focusing on immediate safety and stability during transitions.
HR 589, the MAHSA Act, imposes U.S. sanctions on Iran's Supreme Leader, President, and affiliated entities responsible for human rights abuses and terrorism. It targets the Supreme Leader's Office, the President's cabinet, security forces involved in the crackdown following Mahsa Amini's death, and entities financing abuses. The bill requires the President to annually determine and apply existing sanctions - like property blocking and visa bans - against these individuals and entities. This directly affects Iran's top leadership and security apparatus, aiming to hold them accountable for abuses including the Morality Police's role in Amini's detention and the subsequent violent suppression of protests.
HR 549, the Metastatic Breast Cancer Access to Care Act, removes waiting periods for disability and Medicare coverage for people diagnosed with metastatic breast cancer. Specifically, it amends Social Security Act sections to allow immediate eligibility for disability insurance benefits (eliminating the standard waiting period) and immediate Medicare coverage (waiving the 24-month waiting period) for these patients. The bill directly affects individuals with metastatic breast cancer who would otherwise face delays in accessing critical benefits. These changes apply to applications filed or benefits beginning after the bill's enactment date. The law makes no other policy changes beyond these specific eligibility adjustments.
